Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Cancer Biology & Therapy|June 2, 2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myelomaKatelyn G Ponder, Shannon M Matulis, Sadae Hitosugi, et al.
Journal of Medicinal Chemistry|July 9, 2004
Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90Jean-Yves Le Brazidec, Adeela Kamal, David Busch, et al.
Cancer Research|February 9, 2026
The farnesyl transferase inhibitor darlifarnib (KO-2806) re-sensitizes relapsing tumors to RAS inhibitionHetika Vora Patel, Alison Elizabeth Smith, Stacia Chan, et al.
Molecular Cancer Therapeutics|July 31, 2020
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell CarcinomasMara Gilardi, Zhiyong Wang, Marco Proietto, et al.
Scientific Reports|April 23, 2020
Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphomaRuth Alonso-Alonso, Rufino Mondéjar, Nerea Martínez, et al.
The Journal of Clinical Investigation|February 17, 2007
The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteinsChad A Dickey, Adeela Kamal, Karen Lundgren, et al.
Biorxiv : the Preprint Server for Biology|April 10, 2026
Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2A r and NPM1 -m AMLMd Hafiz Uddin, Sandhya Dhiman, Yufen Han, et al.
Molecular Cancer Therapeutics|March 4, 2026
Targeting menin in T-lineage acute lymphoblastic leukemiaKathryn Shimamoto, Diren Arda Karaoglu, Olivia Arnold, et al.
Neoplasia (New York, N.Y.)|March 21, 2025
Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancersDinesh Babu Manikandan, Sankar Jagadeeshan, Sooraj Mathukkada, et al.
Pageof 4